Education
About Us
Working with TipRanks
Follow Us
Allurion Technologies, Inc. (ALUR)
:ALUR
ALUR Stock Chart & Stats
$1.26
-$0.76(-9.72%)
At close: 4:00 PM EST
$1.26
-$0.76(-9.72%)
Day’s Range― - ―
52-Week Range$1.02 - $16.81
Previous CloseN/A
Volume63.90K
Average Volume (3M)327.15K
Market Cap
$14.91M
Enterprise Value$43.17M
Total Cash (Recent Filing)$6.14M
Total Debt (Recent Filing)$33.39M
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Mar 19, 2026EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding9,262,586
10 Day Avg. Volume176,061
30 Day Avg. Volume327,153
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.31
Price to Sales (P/S)0.75
P/FCF Ratio-0.56
Enterprise Value/Market Cap2.89
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit4.11
Enterprise Value/Ebitda-1.29
Forecast
1Y Price Target
$6.00Price Target Upside376.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.04
Revenue Forecast (FY)$14.37M
Bulls Say, Bears Say
Bulls Say
Cost ManagementOperating expenses of $9.4M were down 48% year over year, as the company continues to closely control spending while prioritizing its growth initiatives.
Sales PerformanceQ3 sales were $2.7M vs the $2.1M Street estimate.
Strategic RealignmentALUR used the quarter to implement the strategy it outlined in August of realigning toward distributors with physician networks that prescribe GLP-1s.
Bears Say
Gross Margin DeclineQ3 gross margin was 49%, down from 58% last year due to the decline in sales and lower production volumes leading to less absorption of labor and overhead costs.
Revenue ShortfallRevenue was $3.4M, which fell short of the $5.2M consensus.
Sales ImpactSales were hurt by the intra-quarter decision to realign toward distributors with physician networks that prescribe GLP-1s.
Allurion Technologies News
ALUR FAQ
What was Allurion Technologies, Inc.’s price range in the past 12 months?
Allurion Technologies, Inc. lowest stock price was $1.02 and its highest was $16.81 in the past 12 months.
What is Allurion Technologies, Inc.’s market cap?
Allurion Technologies, Inc.’s market cap is $14.91M.
When is Allurion Technologies, Inc.’s upcoming earnings report date?
Allurion Technologies, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 111 days.
How were Allurion Technologies, Inc.’s earnings last quarter?
Allurion Technologies, Inc. released its earnings results on Nov 12, 2025. The company reported -$1.53 earnings per share for the quarter, beating the consensus estimate of -$1.97 by $0.44.
Is Allurion Technologies, Inc. overvalued?
According to Wall Street analysts Allurion Technologies, Inc.’s price is currently Undervalued.
Does Allurion Technologies, Inc. pay dividends?
Allurion Technologies, Inc. does not currently pay dividends.
What is Allurion Technologies, Inc.’s EPS estimate?
Allurion Technologies, Inc.’s EPS estimate is -0.91.
How many shares outstanding does Allurion Technologies, Inc. have?
Allurion Technologies, Inc. has 9,262,586 shares outstanding.
What happened to Allurion Technologies, Inc.’s price movement after its last earnings report?
Allurion Technologies, Inc. reported an EPS of -$1.53 in its last earnings report, beating expectations of -$1.97. Following the earnings report the stock price went up 0.671%.
Which hedge fund is a major shareholder of Allurion Technologies, Inc.?
Currently, no hedge funds are holding shares in ALUR
Company Description
Allurion Technologies, Inc.
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
ALUR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in the FDA approval process and successful restructuring efforts that improved financial efficiencies. However, these positives were tempered by a considerable decline in revenue and gross profit. The company's strategic initiatives, such as debt restructuring and R&D advancements, indicate a positive long-term outlook.View all ALUR earnings summariesALUR Stock 12 Month Forecast
Average Price Target
$6.00
▲(376.19% Upside)
Technical Analysis
Ownership Overview
5.20% Insiders
1.05% Mutual Funds
33.62% Other Institutional Investors
59.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---